Irinotecan Hydrochloride, Fluorouracil, and Leucovorin Calcium With or Without Zibotentan in Treating Patients With Metastatic Colorectal Cancer

NCT ID: NCT01205711

Last Updated: 2014-07-08

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 111 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2010-04-30
• Study Completion Date: 2012-09-30

Brief Summary

RATIONALE: Drugs used in chemotherapy, such as irinotecan hydrochloride, fluorouracil, and leucovorin calcium, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Zibotentan may be effective in treating metastatic colorectal cancer that has not responded to oxaliplatin. It is not yet known whether combination chemotherapy is more effective when given with or without zibotentan in treating metastatic colorectal cancer.

PURPOSE: This randomized phase II trial is studying giving irinotecan hydrochloride together with fluorouracil and leucovorin calcium to see how well it works when given with or without zibotentan in treating patients with metastatic colorectal cancer.

Detailed Description

OBJECTIVES:

Primary

• To establish the anti-tumor activity of the combination of irinotecan hydrochloride, fluorouracil, and leucovorin calcium (FOLFIRI) with zibotentan (FOLFERA) as measured by progression-free survival (time-to-event) in patients with metastatic colorectal cancer after failure of oxaliplatin-containing chemotherapy.

Secondary

• To determine the toxicity profile of FOLFERA and of maintenance zibotentan in these patients.
• To determine the feasibility of use of this regimen in these patients.
• To collect tumor and blood samples for future translational work, including investigating endothelian A receptor (ETAR) expression, k-RAS/b-RAF status and alterations in relevant pathways such as Akt, MAPK/ERK.

OUTLINE: This is a multicenter study. Patients are stratified according to study site. Patients are randomized to 1 of 2 treatment arms.

• Arm A: Patients receive irinotecan hydrochloride IV over 1 hour and leucovorin calcium IV over 2 hours on day 1; fluorouracil IV over 46 hours beginning on day 1; and an oral placebo tablet once daily on days 1-14. Treatment repeats every 14 days for 12 courses in the absence of disease progression or unacceptable toxicity. Patients achieving at least stable disease then receive oral placebo alone once daily in the absence of disease progression or unacceptable toxicity.
• Arm B: Patients receive irinotecan hydrochloride IV over 2 hours, leucovorin calcium IV over 2 hours on day 1; fluorouracil IV over 46 hours beginning on day 1; and oral zibotentan once daily on days 1-14. Treatment repeats every 14 days for 12 courses in the absence of disease progression or unacceptable toxicity. Patients achieving at least stable disease then receive oral zibotentan alone once daily in the absence of disease progression or unacceptable toxicity.

Blood and tissue samples are collected periodically for pharmacogenetic, translational, and biomarker correlative studies.

After completion of study therapy, patients are followed up at 30 days and then every 12 weeks for up to 1 year.

Peer Reviewed and Funded or Endorsed by Cancer Research UK

Conditions

Colorectal Cancer

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Interventions

FOLFIRI regimen

Intervention Type: DRUG

fluorouracil

Intervention Type: DRUG

irinotecan hydrochloride

Intervention Type: DRUG

leucovorin calcium

Intervention Type: DRUG

zibotentan

Intervention Type: DRUG

laboratory biomarker analysis

Intervention Type: OTHER

pharmacogenomic studies

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

DISEASE CHARACTERISTICS:

• Histologically or cytologically confirmed colorectal cancer

• Metastatic disease with no bone metastases
• Must have progressed within 6 months of adjuvant oxaliplatin-containing chemotherapy and have no significant ongoing toxicity (excluding grade 1 neurotoxicity)
• Measurable disease by RECIST criteria
• No known brain or leptomeningeal metastases

• Stable disease following surgical resection or radiosurgery of oligometastases allowed

PATIENT CHARACTERISTICS:

• ECOG performance status 0-1
• Life expectancy ≥ 12 weeks
• Hemoglobin ≥ 9.0 g/dL (no prior transfusion) OR ≥ 10.0 g/dL (transfusion within past 4 weeks)
• Absolute neutrophil count ≥ 1.5 times 10^9/L
• Platelet count ≥ 100 times 10^9/L
• Total bilirubin < 1.5 times upper limit of normal (ULN)
• AST and ALT ≤ 2.5 times ULN (≤ 5 times ULN with liver metastases)
• Creatinine clearance ≥ 50 mL/min
• Negative pregnancy test
• Not pregnant or nursing
• Fertile patients must use effective double-method contraception during and for 3 months (female) or 2 months (male) after completion of study treatment
• No active infection or serious concurrent medical condition
• No significant cardiovascular disease including any of the following:

• History of NYHA class II-IV congestive heart failure requiring therapy
• History of unstable angina pectoris or myocardial infarction within the past 6 months
• Severe valvular heart disease
• Ventricular arrhythmia requiring treatment
• Prolonged QTc interval > 470 msec
• No concurrent medical condition, that in the investigator's judgement, will substantially increase the risk associated with the patient's participation in the study, or potentially hamper compliance with the study protocol and follow-up schedule
• No psychiatric disorders or altered mental status precluding understanding of the informed consent process and/or compliance with the study protocol
• No gastrointestinal disorders likely to interfere with absorption of the study drug (e.g., partial bowel obstruction or malabsorption)
• No known serological positivity for hepatitis B or hepatitis C
• No immunocompromised patients (e.g., no known serological positivity for HIV)
• No other prior or current malignant disease likely to interfere with protocol treatment or comparisons

PRIOR CONCURRENT THERAPY:

• See Disease Characteristics
• No prior zibotentan or irinotecan hydrochloride
• More than 4 weeks since prior chemotherapy, radiotherapy (except for palliative reasons), endocrine therapy, or immunotherapy
• No more than 1 prior course of chemotherapy for metastatic disease
• No prior extensive radiotherapy (i.e., likely to deplete bone marrow reserve)
• At least 4 weeks since prior major surgery and recovered
• Concurrent corticosteroids allowed provided the dose is stable for 4 weeks and not altered during the first 15 days of this study
• No concurrent warfarin

• Low molecular weight heparin allowed

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Cardiff University

OTHER

Sponsor Role: lead

Responsible Party

Dr Anne Thomas

Dr

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Anne Thomas, MD

Role: PRINCIPAL_INVESTIGATOR

University Hospitals, Leicester

Locations

Leicester Royal Infirmary

Leicester, England, United Kingdom

Centre for Cancer Research and Cell Biology at Queen's University Belfast

Belfast, Northern Ireland, United Kingdom

Wales Cancer Trials Unit

Cardiff, Wales, United Kingdom

Velindre Cancer Center at Velindre Hospital

Cardiff, Wales, United Kingdom

Countries

United Kingdom

Other Identifiers

WCTU-FOLFERA

Identifier Type: -

Identifier Source: secondary_id

EUDRACT-2009-012151-23

Identifier Type: -

Identifier Source: secondary_id

ISRCTN-73199181

Identifier Type: -

Identifier Source: secondary_id

CRUK-09/023

Identifier Type: -

Identifier Source: secondary_id

WCTU-SPON-671-09

Identifier Type: -

Identifier Source: secondary_id

EU-21071

Identifier Type: -

Identifier Source: secondary_id

ZENECA-WCTU-FOLFERA

Identifier Type: -

Identifier Source: secondary_id

CDR0000685062

Identifier Type: -

Identifier Source: org_study_id